CNN TürkABD üssünde gece yarısı gelen ihbar neydi? | 85 hane boşaltıldıPunchMessi scores 76th free-kick goal, moves within two of all-time recordThe Jerusalem PostIran suspected in bomb plot against RAF base used by US Air Force, UK police investigating - reportInquirerITCZ to bring rains, thunderstorms to Visayas, Mindanao on MondayESPNPayton: Broncos can't keep relying on comebacksBollywood HungamaEXCLUSIVE: Srikanth makers Tushar Hiranandani and Nidhi Parmar Hiranandani announce Ragda 25; film based on Indian Army’s first experimental batch of 25 womenESPN Deportes'Chino' Huerta sufre amargo regreso a CUDaily MaverickBOOK REVIEW: Half Lives — Exploring intimate-partner violence and migration with nuanced sensitivity한겨레보금자리론, 부부 중 1인 소득 7천만원 이하면 신청 가능해진다SözcüAKP’li Kaya’nın malvarlığı araştırılacak mı?النهارصياغة الصمتThe Japan TimesNGO recruiting four-legged ‘specialist’ to help deal with bear incidents
The Daily Newsstand · Free, Always
Monday, September 28, 2026

Top stocks to buy: Stock recommendations for this week - check list

Translate

Top stocks to buy: Stock recommendations for September 28, 2026 week - check list

Top stocks to buy today for the September 28, 2026 week

Stock market recommendations: Pearl Global, and Indegene - these are the top stocks you can consider buying for the week starting September 28, 2026, as recommended by Motilal Oswal Wealth Management Research Desk. Below are the details:

NAMECMP (Rs)TP (Rs)Upside (%)
Pearl Global1318150014%
Indegene60870816%

Pearl GlobalPGIL is scaling its manufacturing capacity to support the next leg of growth, with capacity planned to increase from ~108m pieces to 120–140m by FY28 & 170–175m by FY30, at ~80% utilization.

Higher wallet share from existing customers, a broader product portfolio & expansion across key manufacturing geographies are additional growth drivers.PGIL plans a total of Rs 6.75-7.25b capex through FY30, of which Rs 3.25-3.50b is earmarked for capacity expansion and Rs 3.5-3.75b for investments in knitting and dyeing. Knits are targeted to increase from ~26% to ~35% of capacity, while washing outsourcing is expected to decline from ~60% to 20-25%, supporting margin expansion.We estimate revenue/EBITDA/PAT CAGR of 17%/32%/38% over FY26-FY28, with EBITDA margins expected to expand to 12–14% and RoCE to 22–25%. Management targets Rs 90–100b revenue by FY30, implying 16–18% growth from FY26, with capacity additions, product diversification & higher wallet share driving the outlook.IndegeneIndegene is well positioned to benefit from rising pharma outsourcing, as expanding drug pipelines, clinical complexity and regulatory pressures drive life sciences companies to focus internal resources on core R&D.

Its integrated platform spans clinical, regulatory, medical and commercial operations, covering the commercialization lifecycle from evidence generation to lifecycle optimization, supported by a common data, analytics and technology backbone.Operationally, Indegene remains in the top quartile, given superior revenue per employee. We estimate a CAGR of ~19%/29%/27% in revenue/EBIT/PAT over FY26-28. EBITDA margin is set to recover to 19-20% by 4QFY27, aided by operating leverage. We upgrade our rating to BUY.(Disclaimer: Recommendations and views on the stock market, or any other asset classes or personal finance management tips given by experts and analysts are their own. These opinions do not represent the views of The Times of India.)

View the original on Times of India →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.